Antisense microRNA185 loaded liposome for efficient inhibition of the hepatic endogenous microRNA185 level

Dan Wang,Xuelei Wang,Li Wang,Jin Zhang,Jie Ma,Guimin Xia,Bin Hong

DOI: https://doi.org/10.1016/j.ejps.2021.105803

IF: 5.112

2021-06-01

European Journal of Pharmaceutical Sciences

Abstract:MicroRNA185 (miR185), an endogenous noncoding RNA with 23 nucleotides, is one of key posttranscriptional modulators of cholesterol metabolism in hepatic cells. The antisense inhibitor of miR185 (miR185i) could decrease cholesterol level in vivo, providing a promising agent for anti-atherosclerosis strategy. In this work, a novel LipomiR185i was constructed by thin film hydration method and post-PEGylation as DOPE: DOTAP: Chol: DSPE-PEG2000 at the molar ratio of 1:1:1:0.1 with a nitrogen-to-phosphate ratio of 3, through the optimization of three cationic lipids (DOTAP, DODMA and DLin-MC3-DMA), six helper lipids (PC-98T, HSPC, DOPE, DMPC, DPPC and DSPC), different amounts and incorporation approaches of DSPE-PEG2000 and nitrogen-to-phosphate ratio. LipomiR185i was characterized with a particle size of 174 ± 11 nm, a zeta potential of 7.0 ± 3.3 mV, high encapsulation efficiency and transfection activity. It could protect miR185i from the rapid degradation by nucleases in serum, enhance cellular uptake and promote lysosomal escape in HepG2 cells. LipomiR185i could accumulate in the liver and remain for at least two weeks. More importantly, Lipomir185i significantly down-regulated the hepatic endogenous miR185 level in vitro and in vivo without significant tissue damage at 14 mg•kg−1. The construction of LipomiR185i provides a potential anti-atherosclerotic nanodrug as well as a platform for delivering small RNAs to the liver efficiently and safely.

pharmacology & pharmacy

What problem does this paper attempt to address?

This paper aims to solve the problem of how to efficiently and safely deliver the antisense inhibitor of microRNA185 (miR185), miR185i, to reduce the level of endogenous miR185 in the liver. Specifically, the researchers constructed a new type of liposome (LipomiR185i) loaded with miR185i, and optimized three cationic lipids (DOTAP, DODMA and DLin - MC3 - DMA), six auxiliary phospholipids (PC - 98T, HSPC, DOPE, DMPC, DPPC and DSPC), different amounts and binding methods of DSPE - PEG 2000 and the nitrogen - to - phosphorus ratio (N/P) by using the thin - film hydration method and post - PEGylation technology. Through these optimizations, the researchers successfully prepared LipomiR185i with a small particle size (174 ±11 nm), a moderate ζ - potential (7.0 ±3.3 mV), high encapsulation efficiency and transfection activity. In addition, the study also evaluated the cell uptake, lysosomal escape, serum stability, toxicity and the inhibitory effect on miR185 - decreasing activity in vitro and in vivo of LipomiR185i. The results showed that LipomiR185i could effectively protect miR185i from rapid degradation by nucleases in serum, enhance cell uptake, and promote lysosomal escape in HepG2 cells. More importantly, LipomiR185i could significantly down - regulate the level of endogenous miR185 in the liver in vivo, and no obvious tissue damage was observed at a dose of 14 mg·kg⁻¹. This research result provides a potential approach for the development of anti - atherosclerotic nanomedicines, and also provides a platform for efficiently and safely delivering small RNAs to the liver.

Antisense microRNA185 loaded liposome for efficient inhibition of the hepatic endogenous microRNA185 level

Single‐Vehicular Delivery of Antagomir and Small Molecules to Inhibit miR‐122 Function in Hepatocellular Carcinoma Cells by using “Smart” Mesoporous Silica Nanoparticles

Novel efficacious microRNA-30c analogs reduce apolipoprotein B secretion in human hepatoma and primary hepatocyte cells

Efficient delivery of miR-122 to regulate cholesterol metabolism using a non-covalent peptide-based strategy.

Synthesis of Novel MicroRNA-30c Analogs to Reduce Apolipoprotein B Secretion in Human Hepatoma Cells

Simple and Rational Design of a Polymer Nano-Platform for High Performance of HCV Related Mir-122 Reduction in the Liver

Enhanced Hepatic Delivery of Sirna and Microrna Using Oleic Acid Based Lipid Nanoparticle Formulations

MicroRNA-185 modulates CYP7A1 mediated cholesterol-bile acid metabolism through post-transcriptional and post-translational regulation of FoxO1

Lipid Nanoparticles for Hepatic Delivery of Small Interfering Rna

Deacetylated-poly-N-acetylglucosamine-folic Acid as a Nanocarrier for Delivering miR-196a Inhibitor to Anticancer Activity

MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes

In Vitro Inhibition of Lipoprotein Lipase Gene Expression by RNA Interference

Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia

MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux

Targeted Delivery of Microrna 146b Mimic to Hepatocytes by Lactosylated PDMAEMA Nanoparticles for the Treatment of NAFLD

Delivery of microRNA-33 Antagomirs by Mesoporous Silica Nanoparticles to Ameliorate Lipid Metabolic Disorders

Elaborately engineering of lipid nanoparticle for targeting delivery of siRNA and suppressing acute liver injury

Chenodeoxycholic Acid‐Modified Polyethyleneimine Nano‐Composites Deliver Low‐Density Lipoprotein Receptor Genes for Lipid‐Lowering Therapy by Targeting the Liver

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production

The Distribution and Cell Uptake of Apoa1 Modified Lipid Carriers of Sirna in Mouse Liver in Vivo

Construction and Functional Analysis of Short Interfering RNA Expression Vectors of Targeting Gene Apolipoprotein M